Celgene's Psoriasis Treatment Performs Well In Midstage Study - NASDAQ
Celgene's Psoriasis Treatment Performs Well In Midstage Study - NASDAQ
Celgene Corp.'s (CELG) treatment for moderate-to-severe plaque-type psoriasis performed better than a placebo in a midstage clinical trial, suggesting it holds promise as an oral treatment. In a study of 352 patients, 41% of those receiving the
Source: www.nasdaq.com
Celgene's Psoriasis Treatment Performs Well In Midstage Study - NASDAQ
Celgene Corp.'s (CELG) treatment for moderate-to-severe plaque-type psoriasis performed better than a placebo in a midstage clinical trial, suggesting it holds promise as an oral treatment. In a study of 352 patients, 41% of those receiving the
Source: www.nasdaq.com
Celgene Corp.'s (CELG) treatment for moderate-to-severe plaque-type psoriasis performed better than a placebo in a midstage clinical trial, suggesting it holds promise as an oral treatment. In a study of 352 patients, 41% of those receiving the
Source: www.nasdaq.com
Celgene's Psoriasis Treatment Performs Well In Midstage Study - NASDAQ
Celgene Corp.'s (CELG) treatment for moderate-to-severe plaque-type psoriasis performed better than a placebo in a midstage clinical trial, suggesting it holds promise as an oral treatment. In a study of 352 patients, 41% of those receiving the
Source: www.nasdaq.com
<< Home